April 2018

The Right Drug for the Right Patient: Moving Closer to Truly Personalized Medicine

April 22, 2018

Clinical Articles

Arjun V. Balar, MD, joins Targeted Therapies in Oncology™ to cover the latest developments in cancer therapies that will span new and emerging agents and classes including targeted therapies, immunotherapies, biologics, and cytotoxics, as well as continue to focus on efforts to improve patient selection using biomarkers.

Adoptive Immunotherapy Makes Inroads in Head and Neck Cancers, But Challenges Remain

April 14, 2018

Clinical Articles

Adoptive immunotherapy has shown promising outcomes in early-stage trials for many cancers, but successful approaches in head and neck cancers will require addressing several challenges that are inherent in many solid tumors, such as creating the right homing mechanisms, achieving adequate T-cell infiltration into the tumor, and finding an antigen that will not produce off-tumor effects.

Durvalumab Shows Encouraging Activity in PD-L1-Low HNSCC

April 13, 2018

Clinical Articles

Durvalumab showed encouraging antitumor activity both alone and in combination with tremelimumab for patients with PD-L1–low or –negative recurrent or metastatic head and neck squamous cell carcinoma, according to results of the CONDOR trial presented at the 2018 Multidisciplinary Head and Neck Cancer Symposium in Scottsdale, Arizona.

Promising Activity Seen With Cabozantinib in Radioiodine-Refractory Differentiated Thyroid Carcinoma

April 20, 2018

Clinical Articles

Cabozantinib, a promising multikinase inhibitor, demonstrated encouraging antitumor activity for the treatment of radioiodine-refractory differentiated thyroid carcinoma in the first-line setting, according to the results of a phase II study that were presented at the 2018 Multidisciplinary Head and Neck Cancers Symposium in Scottsdale, Arizona.

A Chemotherapy-Free Option for Advanced Follicular Lymphoma

April 21, 2018

Clinical Articles

The combination of CC-122, an investigational pleiotropic pathway modulator, and the second-generation anti-CD20 antibody obinutuzumab induced strong responses in patients with relapsed or refractory follicular lymphoma.

Early Study Shows Promise for Novel BET Inhibitor in Progressive Lymphomas

April 23, 2018

Clinical Articles

A novel bromodomain and extra terminal protein inhibitor demonstrated promising early activity and a manageable safety profile in the treatment of patients with relapsed or refractory lymphoma in the results of a first-in-human phase I trial.

Prevention of Cytomegalovirus After Allogeneic HSCT

April 26, 2018

Clinical Articles

Two poster presentations at the 2018 BMT Tandem Meetings of the Center for International Blood & Marrow Transplant Research and the American Society for Blood and Marrow Transplantation, provided a compelling extension of the recent phase III clinical trial that demonstrated the efficacy of prophylactic therapy with letermovir (Prevymis) for the prevention of cytomeg alovirus (CMV) infection in patients receiving allogeneic hematopoietic stem cell transplantation (HSCT).

Shingrix Prevents Herpes Zoster Episodes Following HSCT

May 01, 2018

Clinical Articles

A herpes zoster subunit vaccine effectively prevented episodes of HZ and other related complications among patients who had recently underwent autologous hematopoietic stem cell transplant, according to the results of the phase III ZOE-HSCT trial presented at the 2018 BMT Tandem Meetings.

Larotrectinib Excites in TRK Fusion Cancers for Both Adult and Pediatric Patients

April 27, 2018

Clinical Articles

When findings of larotrectinib, a pan-TRK inhibitor co-developed by Bayer and Loxo Oncology, that generated significant excitement for the treatment of both adult and pediatric patients with TRK fusion cancers, were presented during the 2017 ASCO Annual Meeting, the small molecule was lauded as a future standard of care for patients with advanced solid tumors harboring a TRK fusion.

The Right Drug for the Right Patient: Moving Closer to Truly Personalized Medicine

April 01, 2018

Clinical Articles

It is truly an exciting time in cancer research and drug development and it’s a privilege to be able to join Targeted Therapies in Oncology™ and assist an outstanding team of editors and writers to disseminate the most up-to-date, timely and clinically relevant information in this fast-paced era.